Elanco Animal Health (NYSE:ELAN) Insider Timothy Bettington Sells 4,350 Shares of Stock

Key Points

• Insider sale: Elanco insider Timothy Bettington sold 4,350 shares for approximately $100,050 under a pre-arranged Rule 10b5-1 trading plan, reducing his ownership by 3.04% to 138,911 shares.
• Financial performance: Elanco reported quarterly EPS of $0.34, exceeding the $0.27 consensus estimate, while revenue reached $1.37 billion, up 10.2% year over year. The company expects full-year 2026 EPS of $1.10–$1.16.
• Analyst outlook: Analysts maintain a “Moderate Buy” consensus rating with an average price target of $29.91, compared with the stock’s recent price of $23.50; recent targets include $32 from Goldman Sachs and $33 from UBS.

Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) insider Timothy Bettington sold 4,350 shares of the firm's stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $23.00, for a total transaction of $100,050.00. Following the completion of the transaction, the insider owned 138,911 shares in the company, valued at $3,194,953. The trade was a 3.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Elanco Animal Health Stock Performance

ELAN traded down $0.05 during trading on Monday, hitting $23.50. The stock had a trading volume of 2,900,342 shares, compared to its average volume of 5,612,071. The firm has a market cap of $11.74 billion, a PE ratio of -57.31, a P/E/G ratio of 1.68 and a beta of 1.70. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58. Elanco Animal Health Incorporated has a 12 month low of $19.40 and a 12 month high of $27.98. The company has a 50 day simple moving average of $23.22 and a 200-day simple moving average of $23.58.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.27 by $0.07. The company had revenue of $1.37 billion during the quarter, compared to analysts' expectations of $1.31 billion. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The business's quarterly revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the company earned $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Analysts expect that Elanco Animal Health Incorporated will post 1.13 EPS for the current year.

Analysts Set New Price Targets

ELAN has been the topic of several recent analyst reports. The Goldman Sachs Group initiated coverage on Elanco Animal Health in a research report on Friday. They issued a "buy" rating and a $32.00 price target on the stock. KeyCorp reiterated an "overweight" rating on shares of Elanco Animal Health in a report on Wednesday, September 30th. Morgan Stanley increased their price objective on Elanco Animal Health from $23.00 to $26.00 and gave the company an "equal weight" rating in a research report on Wednesday, July 22nd. Piper Sandler restated an "overweight" rating on shares of Elanco Animal Health in a research note on Monday, June 29th. Finally, UBS Group raised their price objective on shares of Elanco Animal Health from $31.00 to $33.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $29.91.

Institutional Trading of Elanco Animal Health

A number of hedge funds have recently modified their holdings of ELAN. Anchor Investment Management LLC bought a new stake in shares of Elanco Animal Health during the second quarter valued at approximately $29,000. Integrated Wealth Concepts LLC acquired a new stake in Elanco Animal Health during the second quarter worth $35,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Elanco Animal Health during the second quarter worth $38,000. Bessemer Group Inc. boosted its stake in Elanco Animal Health by 33.2% during the first quarter. Bessemer Group Inc. now owns 2,105 shares of the company's stock worth $50,000 after buying an additional 525 shares in the last quarter. Finally, Farther Finance Advisors LLC increased its holdings in Elanco Animal Health by 12.5% in the 3rd quarter. Farther Finance Advisors LLC now owns 4,184 shares of the company's stock valued at $94,000 after buying an additional 464 shares during the period. Institutional investors own 97.48% of the company's stock.

About Elanco Animal Health

Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites and support the health and productivity of animals.

The company's products include vaccines, parasiticides, antibiotics, nutritional supplements and other prescription and over-the-counter therapies. Its companion animal offerings address conditions such as flea and tick infestations, internal parasites, osteoarthritis and dermatological disorders, while its farm animal products support the health of cattle, poultry, swine and aquaculture species.

Elanco serves customers in markets around the world through relationships with veterinarians, animal owners, livestock producers, retailers and distributors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.